By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Janssen Biotech Inc. 

800 Ridgeview Drive

Horsham  Pennsylvania  19044  U.S.A.
Phone: 888-227-5624 Fax: n/a


SEARCH JOBS








Company News
Janssen Biotech Inc. (JNJ) To Present New Inflammatory Bowel Disease Data At Digestive Disease Week Meeting 5/16/2016 8:28:03 AM
Janssen Biotech Inc. (JNJ) Release: FDA Expands IMBRUVICA Label To Include New Data From Two Key Phase 3 Trials, Adding Overall Survival And Combination Data 5/9/2016 6:39:12 AM
MorphoSys AG Sues Janssen Biotech Inc. (JNJ) And Genmab A/S (GEN.CO) For Patent Infringement 4/4/2016 11:46:30 AM
X-Chem Announces License With Janssen Biotech Inc. (JNJ) For Protein:Protein Inhibitor Program In Inflammatory Disease 3/30/2016 10:54:15 AM
Janssen Biotech Inc. (JNJ) Release: U.S. FDA Approves IMBRUVICA (ibrutinib) For First-Line Treatment Of Chronic Lymphocytic Leukemia 3/7/2016 6:21:17 AM
Scholar Rock Announces Option Exercised By Janssen Biotech Inc. (JNJ) In Immuno-Oncology Collaboration Focused On Supracellular Activation 1/7/2016 11:15:25 AM
Janssen Biotech Inc. (JNJ) Release: IMBRUVICA (ibrutinib) Phase 2 RESONATE-17 Data Show Robust Clinical Activity And Promising Survival Outcomes In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia With Del 17p 12/8/2015 8:48:57 AM
Janssen Biotech Inc. (JNJ) Release: IMBRUVICA (Ibrutinib) Phase 3 RAY Data Show Significant Improvements In Progression-Free Survival Versus Temsirolimus In Patients With Relapsed Or Refractory Mantle Cell Lymphoma 12/7/2015 7:29:29 AM
Janssen Biotech Inc. (JNJ) Submits Applications Seeking Approval Of STELARA In United States And European Union For Crohn's Disease 11/30/2015 6:51:21 AM
Janssen Biotech Inc. (JNJ) Release: Additional Efficacy And Safety Data For IMBRUVICA (Ibrutinib) Submitted To FDA 11/13/2015 7:26:53 AM
12345678910...
//-->